|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Get up to date information on nutrition and nutrition research from Michael Greger, M.D. at NutritionFacts.org. Click here to view the website!
Granix is now available in the fight against neutropenia during chemotherapy. Click here to view the USPI! Visit www.granixrx.com for more information.
Click here to view the following free CME/CEU program:
Non-Invasive Pre Natal Testing: What Managed Care Needs to Know
Click Here to view the Journal of Managed Care Medicine
Click Here to view our Complimentary Online CME/CEU Webcasts
Announcing the NAMCP Medical Directors Breast Cancer Resource Center. Click here to visit the website.
On Aug 19, 2013, the FDA issued a label change for ADCETRIS® (brentuximab vedotin). Below is a copy of the updated USPI for your review. Key label changes found within the attachments include:
1. Dosage and Administration Section 1: 16 cycle limitation has been removed from the label. New label states "Continue treatment until disease progression or unacceptable toxicity"
2. Warnings and Precautions Section 5: Growth factor support added for consistency with Dose Modification in section 2.2
CLICK HERE to view the USPI.
The Academy of Oncology Nurse Navigators white paper, "Assessing the Creative Application and Usefulness of NSider: A Tactical Tool for the Oncology Nurse Navigator" was published in the journal, The Oncology Nurse-APN/NP.
Click here to view the white paper.
As 2013 comes to a close, GBEMTI would like to wish its members, partners and other industry professionals a safe and happy holiday season. As we reflect on the past year for the industry, we would like to provide the readers of the GBEMTI eNews a look at the most-accessed exclusive content articles from the year. Our regular publication will resume Jan. 9.
How the government shutdown affects healthcare
By Pamela Lewis Dolan
From Oct. 3: The Affordable Care Act, known as Obamacare, is at the center of the budget debate that has resulted in a government shutdown. But one of the ironies of the situation is that the program will remain funded. It even reached a major milestone — the launch of the insurance exchanges — on Oct. 1, the same day other areas of government were forced to place employees on furlough. The ACA, as well as Medicare and Medicaid, are not affected by the shutdown. But other areas of healthcare, particularly those in the public health arena, don’t fall under the same exceptions and were forced into limbo.
Food for thought: How are you perceived professionally?
By Karen Childress
From Oct. 10:
How you are perceived as a physician makes a difference. Fair or not, we’re all judged based on how we present ourselves. Being perceived professionally goes way beyond the wardrobe we choose, however. In many cases, how we are viewed by others is based on more subtle factors. Here are a few items that can impact what others think about you as a professional.
Switch to Sprint and save. Healthcare professionals can save at least 15% monthly with Sprint. Sprint offers special promotions for healthcare employees. With Sprint, you save more and get Truly UnlimitedSM data. Visit www.sprint.com/daretocompare for more details and to start saving today.
5 good things the Affordable Care Act imposed on healthcare
By Mike Wokasch
From Aug. 22: The U.S. healthcare market is well entrenched with operational complexity, an inefficient cost structure and serious quality issues. The diversity of treatment, along with huge, inexplicable variability in costs and how care is paid for make the Affordable Care Act even more challenging to implement. Whether or not you are a fan of "Obamacare," this government-driven initiative has already facilitated five major changes to healthcare.
A closer look at keratoconus
By Dorothy L. Tengler
From May 16: In keratoconus, the normally round cornea becomes thin and irregular or cone-shaped. When this occurs, the abnormal shape prevents the light entering the eye from being focused correctly on the retina, resulting in distortion of vision. The risk of developing keratoconus may be higher in individuals who have certain inherited diseases or genetic conditions, such as Down syndrome, Leber's congenital amaurosis, Ehlers-Danlos syndrome or osteogenesis imperfecta. Over the last several years, significant progress has been made in identifying genetic risk factors for keratoconus.
Health plans in the new healthcare exchanges
By Dr. Jonathan Kaplan
From June 6: If you've been keeping up with the healthcare debate, you'll notice Republicans are predicting the demise of "Obamacare" and Democrats are predicting the Affordable Care Act to be the "second coming." The debate is coming to a fever pitch again because the new healthcare exchanges are about to come to fruition. Starting Oct. 1, consumers will be able to go online and view these different plans. Now that the date is nearing, some state exchanges have released their plan options and their associated premiums from participating insurance companies on the exchange.
Medical device industry facing tough road ahead
By Rosemary Sparacio
From Oct. 17:
The business climate in 2013 and beyond will prove to be a challenging one for medical device manufacturers. And with the current government shutdown centering around the Affordable Care Act, one of the sticking points for passage of the funding bill is removing the steep excise tax on medical devices from the equation by delaying funding for the ACA for at least a year. The industry faces several changes, but the excise tax will have the biggest impact.
Making safe drugs is harder than you think
By Mike Wokasch
From Aug. 15: Whether you manufacture prescription drugs for a pharmaceutical company, compound drug products or prepare solutions in a hospital for administration to patients, you have an obligation to make sure your products are prepared correctly, to deliver the desired dose without doing harm the patient. Aside from the regulatory/legal requirements, there are good reasons for drug companies to adhere to cGMPs when making prescription drugs.
Big Pharma replaces innovation with acquisition
By Mike Wokasch
From Sept 26: Big Pharma, including Big Biotech, has executed about 130 mergers or acquisitions in each of the past couple of years. The overwhelming majority of deals designed to fill depleted Big Pharma pipelines with more novel and innovative technologies in later stages than their own R&D had been able to produce. If Big Pharma is relying on others to do drug discovery, how deep does the discovery pipeline have to go to be indefinitely sustainable?
Amazing new technological advances in healthcare
By Rosemary Sparacio
From April 18: It probably does not surprise anyone just how much technology has affected our daily lives. But the impact of technology in healthcare has been and continues to be nothing short of astounding. And there is always more to come. At the Society of Interventional Radiology's 38th Annual Scientific Meeting, three new treatment advances were discussed: irreversible electroporation, cryoablation and cryoneurolysis. Here is a closer look at what each has to offer.
Promising stem cell treatment for neonatal brain injury and stroke
By Dr. Afsaneh Motamed-Khorasani
From Sept. 12: Human umbilical cord blood is a rich source of stem cells, which could be potentially used for the treatment of hematopoietic diseases. Ischemic brain damage is a major cause of mortality and severe neurologic disability. Recently, the use of human umbilical cord blood for the treatment of neonatal hypoxic-ischemic brain injury and ischemic stroke has been explored in several studies.
"Seizures can be caused by a number of factors, including epilepsy or fever, and most seizures stop themselves, according to the National Institutes of Health."
Missed last week's issue? See which articles your colleagues read most.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063